← All trials
NCT04603495
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 19, 2020
- Primary completion
- Sep 30, 2022
- Completion date
- Sep 30, 2023
- First posted
- Oct 26, 2020
- Last posted
- Nov 24, 2020
- Enrollment
- 310
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Constellation PharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.